GRASP Mentor Registration – ILC23
The 2023 International Invasive Lobular Breast Cancer (ILC) Symposium will be held on September 28-30, 2023 in Pittsburgh, PA. This year’s ILC Symposium will be held as a hybrid conference with both in-person events and live web streaming. The international breast cancer symposium will connect research scientists, clinical oncologists, trainees and fellows, and breast cancer patient advocates and will focus on various topics in primary and metastatic invasive lobular breast cancer (ILC). Ongoing collaborations on the unmet clinical need for people diagnosed and treated each year for ILC is critical for research. GRASP is partnering with the ILC Symposium to bring our signature program of Poster Walkthroughs which will be held virtually after the conference on Oct 5, 2023. Registration for the ILC Symposium is $25 for patient advocates.
Optional Training Sessions
All times shown are Eastern Time (US/New York)
ILC23 GRASP Training
Join us for a training session so that you can be prepared for your upcoming event. Whether joining as a GRASP scientist, poster author, mentor, or patient advocate, these sessions will help you understand your respective role. ...
ABC7 GRASP Training
Join us for a training session so that you can be prepared for your upcoming event. Whether joining as a GRASP scientist, poster author, mentor, or patient advocate, these sessions will help you understand your respective role. ...
No event found!
Virtual GRASP Sessions
*Only sign up for ONE group in each of the 3 sessions below (e.g. Group 1A & 1B are happening at the same time; Group 1A & 2A are not)
Morning Session – Thurs Oct 5, 2023
All times shown are Eastern Time (US/New York)
Group 1A: Chemotherapy
Poster #1: Distinct features of ILC vs IDC in four NSABP randomized trials of adjuvant chemotherapy Poster #2: The effect of (Neo)adjuvant Chemotherapy on Long-Term Survival Outcomes in Invasive Lobular Breast Cancer Patients Treated with Endocrine Therapy: A Retrospective Cohort Study ...
Group 1B: Detection; Patient Advocacy
Poster #1: Personalized Circulating Tumor DNA (ctDNA) Testing for Detection of Progression & Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma (mILC) Poster #2: Enhancing Knowledge & Research in Europe for Invasive Lobular Breast Cancer: Unique Challenges Across European Countries ...
No event found!
Afternoon Session – Thurs Oct 5, 2023
All times shown are Eastern Time (US/New York)
Group 2A: Imaging
Poster #1: Pre-Operative MRI for Screening Digital Breast Tomosynthesis-Detected Invasive Lobular Carcinoma: Who Benefits Most? Poster #2: Contrast-Enhanced Mammography (CEM) Compared to Breast Magnetic Resonance (MRI) In the Management of Breast Lobular Neoplasia: A New Scenario in Facing the Diagnosis of an Insidious Disease ...
Group 2B: Detection; Predictive Biomarkers
Poster #1: Personalized Circulating Tumor DNA (ctDNA) Testing for Detection of Progression & Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma (mILC) Poster #2: Assessing the Effect of E-Cadherin Loss on Estrogen Receptor Activity in Human Mammary Epithelial Cell Models ...
Group 2C: Detection; Tumor Microenvironment
Poster #1: Serial Monitoring of Circulating Tumor Cells & Circulating Tumor DNA in Metastatic Lobular Breast Cancer Identifies Intra-Tumor Heterogeneity & Precision & Immuno-Oncology Biomarkers of Therapeutic Importance Poster #2: Spatially Resolved Analysis of Tumor Microenvironment Revealed Biologically Driven Subgroups with Distinct Clinical Outcome in Invasive Lobular Carcinoma ...
Group 2D: Clinicopathological Features
Poster #1: Overview of Patients with Invasive Lobular Breast Carcinoma Included in the Post-Mortem Tissue Donation Program, UPTIDER Poster #2: Lobular-Like Invasive Mammary Carcinoma: Is this a Ductal Cancer, Lobular Cancer, or a Distinct Entity? ...
Group 2E: Treatment Resistance
Poster #1: Characterization of Resistance to CDK4/6 Inhibitors & Endocrine Therapy in Invasive Lobular Breast Cancer Cell Lines Poster #2: Clinical Characteristics & Outcomes of Invasive Lobular Carcinoma ...
Group 2F: Sikora Lab
Poster #1: The Tumorigenic Effects of E-Cadherin Loss in Early ILC Tumorigenesis Poster #2: WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Invasive Lobular Carcinoma Cells ...
No event found!
Evening Session – Thurs Oct 5, 2023
All times shown are Eastern Time (US/New York)
Group 3A: Lee/Oesterreich Lab
Poster #1: Transcriptomic Analysis Identifies Enrichment of cAMP/PKA/CREB Signaling in Invasive Lobular Breast Cancer Poster #2: Predicting Response to HER2 Tyrosine Kinase Inhibitors & Antibody Drug Conjugates in ERBB2 Mutant ILC Using CRISPR/Cas9 Knock-In Cell Lines & Patient-Derived Organoids ...
Group 3B: Treatment Resistance
Poster #1: Downregulation of Arginosuccinate Synthase 1 Confers Tamoxifen Resistance in Invasive Lobular Breast Cancer Poster #2: Coupling Bioengineered Microsystems with High-Resolution Microscopy to Investigate Dormancy & Drug Resistance in Invasive Lobular Carcinoma ...
Group 3C: Tumor profiling
Poster #1: Reporting on Invasive Lobular Carcinoma in Clinical Drug Trials & Trials Investigating Gene Expression Profiles & Molecular Screening Programs – A Systematic Review Poster #2: Development of a Comprehensive Cancer Profiling Assay Utilizing Circulating Tumor Cells in Metastatic Breast Cancer ...
Group 3D: Sikora Lab
Poster #1: Estrogen Receptor Interaction with Mediator of DNA Damage Checkpoint 1 (MDC1) Mediates Epigenomic Remodeling & Gene Regulation in ILC Cells Poster #2: Efficacy of PARP inhibitor Talazoparib on ER+ ILC Breast Cancer Models ...
Group 3E: Lee/Oesterreich Lab
Poster #1: Spatial Profiling of Mixed Invasive Ductal-Lobular Carcinoma Reveals Intrinsic Molecular Subtype & Oncogenic Signaling Heterogeneity Poster #2: Multi-Omic Characterization of ILC & ILC-Like Cell Lines as part of ILC Cell Line Encyclopedia (ICLE) Defines New Models to Study Potential Biomarkers & Explore Therapeutic Opportunities ...
No event found!
